WE DO NOT SHIP TO RESIDENTIAL ADDRESSES. For pricing in CAD/AUD/NZD please contact us.

Recombinant Human Osteoprotegerin/TNFRSF11B Protein (His Tag)(Active) - PKSH031716

Recombinant Human Osteoprotegerin/TNFRSF11B Protein (His Tag)(Active) - PKSH031716

Regular price
$749.00
Regular price
Sale price
$749.00
Unit price
per 
Availability
Sold out

Recombinant Human Osteoprotegerin/TNFRSF11B Protein (His Tag)(Active)

Size: 100μg

Catalogue Number: PKSH031716-100

Citations, Manuals and MSDS Available upon request.

Abbreviation: Osteoprotegerin; TNFRSF11B

Target Symptom: Tumor necrosis factor receptor superfamily member 11B; Osteoclastogenesis inhibitory factor; Osteoprotegerin; TNFRSF11B; OCIF; OPG; PDB5; TR1

Research Area: Signal Transduction; Cardiovascular; immunology; metabolism;

Target Species: Human

Expression Host: HEK293 Cells

Application: Cell culture; ELISA

Fusion Tag: C-His

Accession: NP_002537.3

Background: Osteoprotegerin or TNFRSF11B is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. Osteoprotegerin/TNFRSF11B acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. This protein may inhibit the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. Osteoprotegerin/TNFRSF11B also play a role in preventing arterial calcification, act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.

Activity: 1. Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is typically 5-20 ng/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10.
2. Immobilized human TNFRSF11B-His at 10 μg/ml (100 μl/well) can bind human Fc-TNFSF11 with a linear ranger of 3. 125-200 ng/mL.

Sequence: Met 1-Leu 401

Purity: > 97 % as determined by reducing SDS-PAGE.

Formulation: Lyophilized from sterile PBS, pH 7.4
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Reconstitution: Please refer to the printed manual for detailed information.

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 45.3 kDa

Observed MW: 55 kDa

Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Research Use Only